These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 30721410)
1. Evolution of Average European Medicine Prices: Implications for the Methodology of External Price Referencing. Vogler S; Schneider P; Zimmermann N Pharmacoecon Open; 2019 Sep; 3(3):303-309. PubMed ID: 30721410 [TBL] [Abstract][Full Text] [Related]
2. Impact of changes in the methodology of external price referencing on medicine prices: discrete-event simulation. Vogler S; Schneider P; Lepuschütz L Cost Eff Resour Alloc; 2020 Nov; 18(1):51. PubMed ID: 33292293 [TBL] [Abstract][Full Text] [Related]
3. Price comparison of high-cost originator medicines in European countries. Vogler S; Zimmermann N; Babar ZU Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):221-230. PubMed ID: 27658050 [TBL] [Abstract][Full Text] [Related]
4. Is Europe still heading to a common price level for on-patent medicines? An exploratory study among 15 Western European countries. Leopold C; Mantel-Teeuwisse AK; Vogler S; de Joncheere K; Laing RO; Leufkens HG Health Policy; 2013 Oct; 112(3):209-16. PubMed ID: 24060335 [TBL] [Abstract][Full Text] [Related]
5. Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis. Iyengar S; Tay-Teo K; Vogler S; Beyer P; Wiktor S; de Joncheere K; Hill S PLoS Med; 2016 May; 13(5):e1002032. PubMed ID: 27243629 [TBL] [Abstract][Full Text] [Related]
6. Overview of external reference pricing systems in Europe. Rémuzat C; Urbinati D; Mzoughi O; El Hammi E; Belgaied W; Toumi M J Mark Access Health Policy; 2015; 3():. PubMed ID: 27123181 [TBL] [Abstract][Full Text] [Related]
7. Analysis of Medicine Prices in New Zealand and 16 European Countries. Vogler S; Kilpatrick K; Babar ZU Value Health; 2015 Jun; 18(4):484-92. PubMed ID: 26091603 [TBL] [Abstract][Full Text] [Related]
8. Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study. Vogler S; Vitry A; Babar ZU Lancet Oncol; 2016 Jan; 17(1):39-47. PubMed ID: 26670089 [TBL] [Abstract][Full Text] [Related]
9. [Risk sharing methods in middle income countries]. Inotai A; Kaló Z Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986 [TBL] [Abstract][Full Text] [Related]
10. Impact of external price referencing on medicine prices - a price comparison among 14 European countries. Leopold C; Mantel-Teeuwisse AK; Seyfang L; Vogler S; de Joncheere K; Laing RO; Leufkens H South Med Rev; 2012 Dec; 5(2):34-41. PubMed ID: 23532710 [TBL] [Abstract][Full Text] [Related]
11. Comparing pharmaceutical pricing and reimbursement policies in Croatia to the European Union Member States. Vogler S; Habl C; Bogut M; Voncina L Croat Med J; 2011 Apr; 52(2):183-97. PubMed ID: 21495202 [TBL] [Abstract][Full Text] [Related]
12. Differences in external price referencing in Europe: a descriptive overview. Leopold C; Vogler S; Mantel-Teeuwisse AK; de Joncheere K; Leufkens HG; Laing R Health Policy; 2012 Jan; 104(1):50-60. PubMed ID: 22014843 [TBL] [Abstract][Full Text] [Related]
13. Impact of cross-reference pricing on pharmaceutical prices: manufacturers' pricing strategies and price regulation. Stargardt T; Schreyögg J Appl Health Econ Health Policy; 2006; 5(4):235-47. PubMed ID: 17249840 [TBL] [Abstract][Full Text] [Related]
14. Implications of external price referencing of pharmaceuticals in Middle East countries. Kaló Z; Alabbadi I; Al Ahdab OG; Alowayesh M; Elmahdawy M; Al-Saggabi AH; Tanzi VL; Al-Badriyeh D; Alsultan HS; Ali FM; Elsisi GH; Akhras KS; Vokó Z; Kanavos P Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):993-8. PubMed ID: 26088919 [TBL] [Abstract][Full Text] [Related]
15. Enhancing medicine price transparency through price information mechanisms. Hinsch M; Kaddar M; Schmitt S Global Health; 2014 May; 10():34. PubMed ID: 24885767 [TBL] [Abstract][Full Text] [Related]
16. Pricing policies for generic medicines in Australia, New Zealand, the Republic of Korea and Singapore: patent expiry and influence on atorvastatin price. Roughead EE; Kim DS; Ong B; Kemp-Casey A WHO South East Asia J Public Health; 2018 Sep; 7(2):99-106. PubMed ID: 30136668 [TBL] [Abstract][Full Text] [Related]
17. Comparison of US and EU Prices for Orphan Drugs in the Perspective of the Considered US Orphan Drugs Act Modifications and Discussed Price-Regulation Mechanisms Adjustments in US and European Union. Żelewski P; Wojna M; Sygit K; Cipora E; Gąska I; Niemiec M; Kaczmarski M; Banaś T; Karakiewicz B; Kotwas A; Zabielska P; Partyka O; Pajewska M; Krzych-Fałta E; Bandurska E; Ciećko W; Czerw A Int J Environ Res Public Health; 2022 Sep; 19(19):. PubMed ID: 36231399 [TBL] [Abstract][Full Text] [Related]
18. Differential pricing of new pharmaceuticals in lower income European countries. Kaló Z; Annemans L; Garrison LP Expert Rev Pharmacoecon Outcomes Res; 2013 Dec; 13(6):735-41. PubMed ID: 24219049 [TBL] [Abstract][Full Text] [Related]
19. Granting marketing authorisation for medicines in South East European countries: the point of view of the authority. Tomić S; Sucić AF; Martinac AI Regul Toxicol Pharmacol; 2010; 57(2-3):325-32. PubMed ID: 20385190 [TBL] [Abstract][Full Text] [Related]
20. Review of studies reporting actual prices for medicines. Mardetko N; Kos M; Vogler S Expert Rev Pharmacoecon Outcomes Res; 2019 Apr; 19(2):159-179. PubMed ID: 30468097 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]